Cellectis SA Net Income
| CLLS Stock | USD 3.73 0.19 5.37% |
As of the 5th of February, Cellectis shows the Downside Deviation of 4.68, mean deviation of 3.75, and Risk Adjusted Performance of 0.0308. Cellectis SA technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cellectis SA downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Cellectis SA is priced correctly, providing market reflects its regular price of 3.73 per share. Given that Cellectis has jensen alpha of 0.1113, we suggest you to validate Cellectis SA's prevailing market performance to make sure the company can sustain itself at a future point.
Cellectis Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.7374 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -33 M | -34.7 M | |
| Net Loss | -33.1 M | -34.7 M | |
| Net Loss | -95.5 M | -100.3 M | |
| Net Loss | (0.47) | (0.49) | |
| Net Income Per E B T | 0.78 | 0.62 |
Cellectis | Net Income | Build AI portfolio with Cellectis Stock |
The evolution of Net Income for Cellectis SA provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Cellectis compares to historical norms and industry peers.
Latest Cellectis' Net Income Growth Pattern
Below is the plot of the Net Income of Cellectis SA over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cellectis SA financial statement analysis. It represents the amount of money remaining after all of Cellectis SA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cellectis' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cellectis' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (36.7 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cellectis Net Income Regression Statistics
| Arithmetic Mean | (56,898,147) | |
| Geometric Mean | 30,940,506 | |
| Coefficient Of Variation | (60.73) | |
| Mean Deviation | 30,995,137 | |
| Median | (63,918,220) | |
| Standard Deviation | 34,554,760 | |
| Sample Variance | 1194T | |
| Range | 101.1M | |
| R-Value | (0.35) | |
| Mean Square Error | 1116.4T | |
| R-Squared | 0.12 | |
| Significance | 0.17 | |
| Slope | (2,404,573) | |
| Total Sum of Squares | 19104.5T |
Cellectis Net Income History
Other Fundumenentals of Cellectis SA
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cellectis Net Income component correlations
Cellectis Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cellectis is extremely important. It helps to project a fair market value of Cellectis Stock properly, considering its historical fundamentals such as Net Income. Since Cellectis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cellectis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cellectis' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Cellectis introduce new products? Factors like these will boost the valuation of Cellectis. Projected growth potential of Cellectis fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Cellectis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Revenue Per Share | Quarterly Revenue Growth 1.059 | Return On Assets | Return On Equity |
The market value of Cellectis SA is measured differently than its book value, which is the value of Cellectis that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectis' value that differs from its market value or its book value, called intrinsic value, which is Cellectis' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Cellectis' market value can be influenced by many factors that don't directly affect Cellectis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cellectis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cellectis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cellectis' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cellectis 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cellectis' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cellectis.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Cellectis on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Cellectis SA or generate 0.0% return on investment in Cellectis over 90 days. Cellectis is related to or competes with Alto Neuroscience, AC Immune, Aldeyra, Amarin PLC, Alpha Tau, Larimar Therapeutics, and Silence Therapeutics. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cell... More
Cellectis Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cellectis' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cellectis SA upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.68 | |||
| Information Ratio | 0.0177 | |||
| Maximum Drawdown | 29.31 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 9.24 |
Cellectis Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectis' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cellectis' standard deviation. In reality, there are many statistical measures that can use Cellectis historical prices to predict the future Cellectis' volatility.| Risk Adjusted Performance | 0.0308 | |||
| Jensen Alpha | 0.1113 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0193 | |||
| Treynor Ratio | 0.234 |
Cellectis February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0308 | |||
| Market Risk Adjusted Performance | 0.244 | |||
| Mean Deviation | 3.75 | |||
| Semi Deviation | 4.6 | |||
| Downside Deviation | 4.68 | |||
| Coefficient Of Variation | 3307.3 | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.29 | |||
| Information Ratio | 0.0177 | |||
| Jensen Alpha | 0.1113 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0193 | |||
| Treynor Ratio | 0.234 | |||
| Maximum Drawdown | 29.31 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 9.24 | |||
| Downside Variance | 21.94 | |||
| Semi Variance | 21.15 | |||
| Expected Short fall | (4.28) | |||
| Skewness | 0.1691 | |||
| Kurtosis | 1.19 |
Cellectis SA Backtested Returns
Cellectis appears to be risky, given 3 months investment horizon. Cellectis SA secures Sharpe Ratio (or Efficiency) of 0.0588, which signifies that the company had a 0.0588 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Cellectis SA, which you can use to evaluate the volatility of the firm. Please makes use of Cellectis' Mean Deviation of 3.75, downside deviation of 4.68, and Risk Adjusted Performance of 0.0308 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cellectis holds a performance score of 4. The firm shows a Beta (market volatility) of 0.62, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cellectis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cellectis is expected to be smaller as well. Please check Cellectis' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Cellectis' price patterns will revert.
Auto-correlation | -0.39 |
Poor reverse predictability
Cellectis SA has poor reverse predictability. Overlapping area represents the amount of predictability between Cellectis time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cellectis SA price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Cellectis price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.39 | |
| Spearman Rank Test | -0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cellectis Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cellectis SA reported net income of (36.7 Million). This is 110.75% lower than that of the Biotechnology sector and 152.39% lower than that of the Health Care industry. The net income for all United States stocks is 106.43% higher than that of the company.
Cellectis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectis' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics of similar companies.Cellectis is currently under evaluation in net income category among its peers.
Cellectis Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cellectis from analyzing Cellectis' financial statements. These drivers represent accounts that assess Cellectis' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cellectis' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 379.2M | 96.8M | 160.4M | 151.7M | 136.5M | 129.7M | |
| Enterprise Value | 295.3M | 82.0M | 108.7M | 99.9M | 89.9M | 85.4M |
Cellectis ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cellectis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cellectis' managers, analysts, and investors.Environmental | Governance | Social |
Cellectis Institutional Holders
Institutional Holdings refers to the ownership stake in Cellectis that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cellectis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cellectis' value.| Shares | Wells Fargo & Co | 2025-06-30 | 17.1 K | Harbour Investments, Inc. | 2025-06-30 | 4.5 K | Rhumbline Advisers | 2025-06-30 | 1.9 K | Jpmorgan Chase & Co | 2025-06-30 | 1.8 K | Hanson Mcclain Inc | 2025-06-30 | 500 | Pom Investment Strategies, Llc | 2025-06-30 | 495 | Principal Securities Inc | 2025-06-30 | 179 | Advisor Group Holdings, Inc. | 2025-06-30 | 100.0 | Bank Of America Corp | 2025-06-30 | 77.0 | Long Focus Capital Management, Llc | 2025-06-30 | 4.7 M | B Group, Inc | 2025-06-30 | 3.3 M |
Cellectis Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0447 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 293.04 M | ||||
| Shares Outstanding | 72.33 M | ||||
| Shares Owned By Institutions | 14.43 % | ||||
| Number Of Shares Shorted | 419.18 K | ||||
| Price To Earning | (14.84) X | ||||
| Price To Book | 3.53 X | ||||
| Price To Sales | 4.37 X | ||||
| Revenue | 41.51 M | ||||
| Gross Profit | 82.55 M | ||||
| EBITDA | (9.46 M) | ||||
| Net Income | (36.7 M) | ||||
| Cash And Equivalents | 153.13 M | ||||
| Cash Per Share | 3.37 X | ||||
| Total Debt | 91.46 M | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 1.39 X | ||||
| Cash Flow From Operations | 22.1 M | ||||
| Short Ratio | 5.00 X | ||||
| Earnings Per Share | (0.33) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 216 | ||||
| Beta | 2.85 | ||||
| Market Capitalization | 360.55 M | ||||
| Total Asset | 383.54 M | ||||
| Retained Earnings | (329.61 M) | ||||
| Working Capital | 120.8 M | ||||
| Current Asset | 51 M | ||||
| Current Liabilities | 26.28 M | ||||
| Net Asset | 383.54 M |
About Cellectis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectis SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.